MedElevator
Войти в исследования Immunotherapy advances · 2026
Comprehensive spatial and immune profiling of metastatic mismatch repair-deficient colorectal cancer reveals response to immunotherapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Ilkyu, Kang Hari, Kim Se-Hee, Jung YunJae, Lee Won-Suk
Аннотация
INTRODUCTION: Mismatch repair-deficient (dMMR) colorectal cancers (CRCs) exhibit variable clinical responses to immune checkpoint inhibitors (ICIs) despite their high immunogenicity.
METHODS: To investigate the molecular and spatial determinants of this heterogeneity, we analyzed five metastatic sites (colon, liver, peritoneum, left ovary, and right ovary) from a dMMR CRC patient treated with pembrolizumab using bulk and single-cell RNA sequencing combined with multiplex immunohistochemistry.
RESULTS: Responsive lesions were characterized by enriched cytotoxic and interferon-γ signatures, greater CD8+ T-cell infiltration, and close spatial proximity between programmed death-ligand 1(PD-L1)+ tumor cells and M1-like macrophages. In contrast, resistant lesions demonstrated reduced effector cell presence and were enriched in immunosuppressive programs, including SPP1+ and CD163+ macrophages, noncanonical WNT5A/B signaling, and TGF-β-mediated matrix remodeling.
CONCLUSION: Collectively, these findings highlight the importance of spatial immune architecture and macrophage polarization in shaping ICI responses in dMMR CRC and underscore the need for spatial profiling to guide immunotherapy strategies in metastatic disease.
METHODS: To investigate the molecular and spatial determinants of this heterogeneity, we analyzed five metastatic sites (colon, liver, peritoneum, left ovary, and right ovary) from a dMMR CRC patient treated with pembrolizumab using bulk and single-cell RNA sequencing combined with multiplex immunohistochemistry.
RESULTS: Responsive lesions were characterized by enriched cytotoxic and interferon-γ signatures, greater CD8+ T-cell infiltration, and close spatial proximity between programmed death-ligand 1(PD-L1)+ tumor cells and M1-like macrophages. In contrast, resistant lesions demonstrated reduced effector cell presence and were enriched in immunosuppressive programs, including SPP1+ and CD163+ macrophages, noncanonical WNT5A/B signaling, and TGF-β-mediated matrix remodeling.
CONCLUSION: Collectively, these findings highlight the importance of spatial immune architecture and macrophage polarization in shaping ICI responses in dMMR CRC and underscore the need for spatial profiling to guide immunotherapy strategies in metastatic disease.